Delcath Systems (DCTH) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 13, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	872,912
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		2,591,509
Document Fiscal Year Focus	2,017
Trading Symbol	DCTH
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)		Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents		$ 2,495,000	$ 4,409,000
Restricted cash		8,362,000	27,287,000
Accounts receivables, net		298,000	403,000
Inventories		1,164,000	660,000
Prepaid expenses and other current assets		385,000	698,000
Deferred financing costs		529,000	699,000
Total current assets		13,233,000	34,156,000
Property, plant and equipment, net		1,253,000	1,083,000
Total assets		14,486,000	35,239,000
Current liabilities
Accounts payable		1,891,000	594,000
Accrued expenses		3,755,000	3,407,000
Series C preferred shares		494,000	0
Convertible notes payable, net of debt discount		9,736,000	13,343,000
Warrant liability		16,000	18,751,000
Total current liabilities		15,892,000	36,095,000
Deferred revenue		0	30,000
Other non-current liabilities		444,000	604,000
Total liabilities		16,336,000	36,729,000
Commitments and Contingencies
Stockholders' deficit
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively		0	0
Common stock, $.01 par value; 500,000,000 shares authorized; 1,426,153 and 11,805 shares issued and 1,425,862 and 11,750 shares outstanding at September 30, 2017 and December 31, 2016, respectively*	[1]	14,000	0
Additional paid-in capital		303,808,000	277,790,000
Accumulated deficit		(305,587,000)	(279,188,000)
Treasury stock, at cost; 1 share at September 30, 2017 and December 31, 2016, respectively*	[1]	(51,000)	(51,000)
Accumulated other comprehensive income		(34,000)	(41,000)
Total stockholders' deficit		(1,850,000)	(1,490,000)
Total liabilities and stockholders' deficit		$ 14,486,000	$ 35,239,000
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	1,426,153	11,805
Common stock, shares outstanding (in shares)	1,425,862	11,750
Treasury stock, at cost (in share)	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue		$ 684,000	$ 435,000	$ 2,011,000	$ 1,316,000
Cost of goods sold		172,000	112,000	527,000	373,000
Gross profit		512,000	323,000	1,484,000	943,000
Operating expenses:
Selling, general and administrative		2,860,000	2,361,000	7,807,000	7,025,000
Research and development		2,279,000	2,686,000	7,119,000	5,975,000
Total operating expenses		5,139,000	5,047,000	14,926,000	13,000,000
Operating loss		(4,627,000)	(4,724,000)	(13,442,000)	(12,057,000)
Change in fair value of the warrant liability, net		27,000	8,680,000	1,227,000	9,171,000
Gain on warrant extinguishment		0	0	9,613,000	0
Loss on debt settlements		(2,952,000)		(2,952,000)	0
Interest expense		(5,042,000)	(4,963,000)	(20,324,000)	(6,584,000)
Other income (expense)		(2,000)	3,000	5,000	(15,000)
Net loss		(12,596,000)	(1,004,000)	(25,873,000)	(9,485,000)
Other comprehensive loss:
Foreign currency translation adjustments		(15,000)	(2,000)	7,000	(12,000)
Comprehensive loss		$ (12,611,000)	$ (1,006,000)	$ (25,866,000)	$ (9,497,000)
Common share data:
Basic and diluted loss per share	[1]	$ (9.36)	$ (230.99)	$ (34.99)	$ (2,232.30)
Weighted average number of basic and diluted common shares outstanding	[1]	1,401,413	4,349	754,421	4,249
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016 and a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016
Reverse stock split ratio		0.0625
Subsequent Event [Member]
Reverse stock split ratio	0.0029

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive loss [Member]
Balance at Dec. 31, 2016	$ (1,490)		$ (51)	$ 277,790	$ (279,188)	$ (41)
Balance (in shares) at Dec. 31, 2016		11,805	(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	48			48
Compensation expense for issuance of restricted stock	84			84
Compensation expense for issuance of restricted stock (in shares)		261
Issuance of common stock for payments made in shares on convertible note payable	25,866	$ 14		25,852
Issuance of common stock for payments made in shares on convertible note payable (in shares)		1,413,790
Series B preferred stock dividend	(526)				(526)
Warrants exercised	15			15
Warrants Exercised (in shares)		297
Fair value of warrants exercised	19			19
Net loss	(25,873)				(25,873)
Total comprehensive loss	7					7
Balance at Sep. 30, 2017	$ (1,850)	$ 14	$ (51)	$ 303,808	$ (305,587)	$ (34)
Balance (in shares) at Sep. 30, 2017		1,426,153	(1)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Stockholders' Deficit) (Unaudited) (Parenthetical)	Nov. 06, 2017	Jul. 21, 2016$ / shares	Sep. 30, 2017$ / shares	Dec. 31, 2016$ / shares
Common stock issued, par value		$ 0.01	$ 0.01	$ 0.01
Reverse stock split ratio		0.0625
Subsequent Event [Member]
Reverse stock split ratio	0.0029

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (25,873,000)	$ (9,485,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	48,000	138,000
Restricted stock compensation expense	84,000	228,000
Depreciation expense	198,000	232,000
Loss on disposal of equipment	20,000	1,000
Warrant liability fair value adjustment	(1,227,000)	(9,171,000)
Gain on warrant extinguishment	(9,613,000)	0
Non-cash interest income	16,000	(1,000)
Deferred revenue	(30,000)	31,000
Debt discount and deferred finance costs amortization	20,315,000	6,567,000
Loss on debt settlements	2,952,000	0
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	276,000	610,000
Increase in accounts receivable	(94,000)	(94,000)
Decrease (increase) in inventories	(338,000)	190,000
Increase in accounts payable and accrued expenses	1,767,000	312,000
Decrease in other non-current liabilities	(160,000)	(155,000)
Net cash used in operating activities	(11,659,000)	(10,597,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(372,000)	(245,000)
Increase in restricted cash	0	(1,087,000)
Net cash used in investing activities	(372,000)	(1,332,000)
Cash flows from financing activities:
Increase in restricted cash	0	(29,200,000)
Net proceeds from the release of restricted cash	7,901,000	0
Net proceeds from sale of Series B and Series C preferred shares	2,278,000	0
Net proceeds from convertible debt financing	0	31,436,000
Net proceeds from sale of stock and exercise of warrants	15,000	704,000
Net cash provided by financing activities	10,194,000	2,940,000
Foreign currency effects on cash and cash equivalents	(77,000)	71,000
Net decrease in cash and cash equivalents	(1,914,000)	(8,918,000)
Cash and cash equivalents:
Beginning of period	4,409,000	12,607,000
End of period	2,495,000	3,689,000
Supplemental non-cash activities:
Conversion of convertible notes to common stock	26,199,000	0
Fair value of warrants issued	0	28,133,000
Fair value of warrants exercised	19,000	245,000
Series A and Series B Preferred Shares [Member]
Cash flows from financing activities:
Release of restricted cash for redemption of Series A and Series B preferred shares	2,360,000	0
Redemption of Series A and Series B preferred shares	(2,360,000)	0
Series C Warrants [Member]
Cash flows from financing activities:
Release of restricted cash for extinguishment of Series C Warrants	7,876,000	0
Cash paid to extinguish of Series C Warrants	$ (7,876,000)	$ 0

General

General	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	(1) General The interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and nine months ended September 30, 2017 and 2016 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“Annual Report”), which has been filed with the Securities Exchange Commission (“SEC”), as amended by that certain Amendment No. 1 to Form 10-K for the year ended December 31, 2016, filed with the SEC on July 14, 2017 and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries. On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split. Description of Business Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is in commercial development under the trade name Delcath Hepatic CHEMOSAT ® ® Our primary research focus is on ocular melanoma liver metastases (mOM) and intrahepatic cholangiocarcinoma (ICC), a type of primary liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. Our clinical development program for CHEMOSAT and Melphalan/HDS is comprised of The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial), a Global Phase 3 clinical trial that is investigating overall survival in mOM, and a registration trial for intrahepatic cholangiocarcinoma (ICC) we plan to initiate in 2017. Our clinical development plan (CDP) also includes a commercial registry for CHEMOSAT non-clinical commercial cases performed in Europe and sponsorship of select investigator initiated trials (IITs) in colorectal cancer metastatic to the liver (mCRC) and pancreatic cancer metastatic to the liver. Liquidity and Operating Matters The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $305.6 $12.6 $11.7 The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016 and effecting a reverse stock split on November 6, 2017 management believes that in its current reduced operating mode its capital resources will be adequate to fund operations through at least January 2018. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel. Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2017 and 2016; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period. Significant Accounting Policies A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventories	(2) Inventories Inventories consist of the following: (in thousands) September 30, 2017 December 31, 2016 Raw materials $ 328 $ 346 Work-in-process 660 214 Finished goods 176 100 Total inventories $ 1,164 $ 660

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses And Other Current Assets	(3) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: (in thousands) September 30, 2017 December 31, 2016 Insurance premiums $ 61 $ 501 Taxes 53 — Security Deposit 50 50 Other 1 221 147 Total prepaid expenses and other current assets $ 385 $ 698 1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at September 30, 2017 and December 31, 2016.

Property, Plant, and Equipment

Property, Plant, and Equipment	9 Months Ended
	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Property, Plant, and Equipment	(4) Property, Plant, and Equipment Property, plant, and equipment consist of the following: (in thousands) September 30, 2017 December 31, 2016 Buildings and land $ 574 $ 556 Enterprise hardware and software 1,648 1,532 Leaseholds 1,659 1,504 Equipment 960 940 Furniture 182 354 Property, plant and equipment, gross 5,023 4,886 Accumulated depreciation (3,770 ) (3,803 ) Property, plant and equipment, net $ 1,253 $ 1,083 Depreciation expense for the three and nine months ended September 30, 2017 was approximately $0.1 million and $0.2 million, respectively, as compared to approximately $0.1 million and $0.2 million, respectively, for the same periods in 2016.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2017
Payables And Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consist of the following: (in thousands) September 30, 2017 December 31, 2016 Clinical trial expenses 1,410 1,365 Compensation, excluding taxes $ 1,132 $ 933 Professional fees 448 286 Short-term portion of lease restructuring 221 216 Other 1 544 607 Total accrued expenses $ 3,755 $ 3,407 1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

Restructuring Expenses

Restructuring Expenses	9 Months Ended
	Sep. 30, 2017
Restructuring And Related Activities [Abstract]
Restructuring Expenses	(6) Restructuring Expenses In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of September 30, 2017, the total remaining lease restructuring liability for its leased office space was approximately $0.7 million, of which approximately $0.3 million and $0.4 million were included in Accrued expenses and Other non-current liabilities on the condensed consolidated balance sheets, respectively. The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017: (in thousands) Lease Liability Reserve balance at December 31, 2016 $ 820 Charges — Payments/Utilizations (155 ) Reserve balance at September 30, 2017 $ 665

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Convertible Notes Payable	(7) Convertible Notes Payable On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default. Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. An additional $6.6 million was released during the three months ended March 31, 2017. Under the terms of warrant repurchase agreements signed in April 2017 and discussed in more detail below, $7.9 million was returned to the holders in exchange for the extinguishment of the Series C Warrants. During the three months ended September 30, 2017, an additional $2.1 million was released to the Company and $2.4 million was returned to the holders in order to redeem the Series A and Series B Preferred Shares discussed in more detail in Note 8. In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire appoximately 20,000 shares of Common Stock. The provisions in the Series C Warrants required the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. On April 2, 2017 the Company entered into separate warrant repurchase agreements (the “Warrant Repurchase Agreements”) with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case were paid to the respective investor, in exchange for cancellation of the Warrants issued to each investor under the SPA. As a result of the extinguishment, the Company recognized a gain of $9.6 million, representing the difference between the fair value of the liability as of the extinguishment date of $17.5 million related to the Series C Warrants and the $7.9 million in cash returned to the Note holders to extinguish the liability. The Company has agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. At any time after the issuance of the Notes, the Notes will be convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $1,536.50, subject to adjustment as provided in the Notes. Restructuring Agreement On August 28, 2017, the Company entered into a Restructuring Agreement (the “Agreement”) with one of the institutional investors (the “Investor”) who was a party to the SPA. As of the date the Agreement was entered into, the Investor held $11,444,637 aggregate principal amount of Notes of which there was $10,092,857 aggregate Restricted Principal, (as defined in the Notes) of Notes (the “Restricted Notes”), secured by such aggregate cash amount held in a collateral account of the Company in the same amount (the “Restricted Cash”) and (y) $1,351,780 principal of Notes (the “Unrestricted Notes”), (ii) 4,200 shares of Series A Preferred Stock and (iii) 2,006 shares of Series B Convertible Preferred Stock. Pursuant to the Agreement, (a) on the date thereof the Company and the Investor took the following actions (the “Initial Restructuring”): (i) the Investor released restrictions on $1,650,000 of Restricted Cash (the “Initial Release”), (ii) the Investor consented to the use of additional Restricted Cash to effect redemptions of the Series A Preferred Shares and the Series B Preferred Shares, (iii) the Investor cancelled $1,200,000 aggregate principal of the Notes (such portion of the Notes, the “Cancellation Note”), (iv) the Company redeemed all the Series A Preferred Shares outstanding for a cash payment to the Investor of $4.20 and (v) the Company redeemed the Series B Preferred Shares for a cash payment to the Investor of $2,006,000 and (b) upon the consummation of a reverse stock split of our Common Stock of at least twenty to one (the “Reverse Stock Split Event”, and such date, the “Reverse Stock Split Date”) by September 15, 2017, the Company and the Investor shall have taken the following actions (the “Additional Restructuring”, and together with the Initial Restructuring, the “Restructuring”): (i) the Investor shall consent to the use of Restricted Cash to effect redemptions of $4,000,000 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Redemption Notes”), (ii) the Company shall redeem the Redemption Notes for a redemption price of $6,436,852.80 (the “Redemption Price”) and (iii) the Company shall exchange (the “Exchange”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, $2,436,852.80 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Exchange Notes”, and together with the Redemption Notes, the “Restructured Notes”) for new warrants to purchase 114,286 shares of its Common Stock (the “New Warrants”, as exercised, the “New Warrant Shares”). The New Warrants expire on the 42 month anniversary of the date of issuance and bear an exercise price of $122.50 per share (which shall be adjusted to the new lower purchase price per share if there is a subsequent “down round” financing). The Investor, in lieu of an exercise of the New Warrants pursuant to a cash payment of the aggregate exercise price of the number of New Warrants being exercised, may exercise the New Warrants, in whole or in part, by electing instead to receive upon such exercise two shares and one hundred and twenty-five thousandths of a share of the Company’s Common Stock for each Warrant Share exercised pursuant to this provision.. The transactions set forth herein were being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 144(d)(3)(ii) of the 1933 Act. As a result of not having effected a reverse stock split by September 15, 2017, the Additional Restructuring did not occur. Amendment to Restructuring Agreement As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,551 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75 th The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows: Number of Shares of Common Stock Number of Shares of Preferred Stock Applicable Conversion Price Reduction in Principal January 12, 2017 11,753 — $ 126.00 $ 1,478,318 January 26 - February 1, 2017 1 4,857 — $ 112.00 544,000 February 10, 2017 43,882 — $ 70.00 3,045,817 February 23 - March 2, 2017 1 2,571 — $ 49.00 126,000 March 13, 2017 117,297 — $ 38.50 4,417,830 April 10, 2017 169,061 — $ 21.00 3,621,286 May 9, 2017 109,367 — $ 17.50 1,913,915 June 7 / July 2, 2017 Exchange Agreement 2 689,796 4,200 $ 6.09 4,200,000 July 7, 2017 114,286 — $ 17.50 2,000,000 August 4, 2017 38,906 — $ 24.50 1,015,848 August 28, 2017 Restructuring Agreement 3 117,171 — $ 10.50 1,200,000 Total 1,418,948 $ 23,563,014 1 2 3 As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants 33.3 put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at September 30, 2017. All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. As of September 30, 2017, the Company had incurred approximately $1.8 million in debt issuance costs and had amortized approximately $1.2 million of those costs. The following table summarizes the convertible notes outstanding at September 30, 2017: (in thousands) Convertible notes payable, principal $ 11,437 Debt discounts (1,701 ) Net convertible note payable $ 9,736

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity	(8) Stockholders’ Equity Stock Issuances Reverse Stock Split On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-three hundred fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.] On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split. In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares. Recent Preferred Stock Issuances Series A Preferred Stock On June 29, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series A Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series A Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series A Preferred Stock”). On July 2, 2017, we entered into an exchange agreement (the “Exchange”) with one of our investors which had purchased certain senior secured convertible notes (the “Notes”), convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock (the “Series A Preferred Shares”). The Exchange was made in reliance upon the exemption from registration provided by Rule 3(a)(9) of the Securities Act of 1933, as amended. The Series A Preferred Shares were entitled to the whole number of votes equal to $4.2 million divided by $1,288.00 (the closing bid price on June 13, 2016, the date of issuance of the Notes as adjusted for the reverse stock split effected in July 2016,) or 3,261 votes. The Series A Preferred Stock had no dividend, liquidation or other preferential rights to our common stock, and each share of Series A Preferred Stock was redeemed for the amount of $0.001, paid in cash pursuant to the Restructuring Agreement signed on August 28, 2017 and discussed in further detail in Note 7. Series B Preferred Stock On June 29, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series B Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series B Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series B Preferred Stock”). On July 11, 2017, we entered into a securities purchase agreement with existing holders of Notes pursuant to which the investors purchased $2,360,000 of Series B Preferred Stock for a cash purchase price of $2,000,000 in a private placement. The Series B Preferred Stock was entitled to the whole number of votes equal to $2.0 million divided by $65.35 (the closing bid price on July 5, 2017, the date of the original securities purchase agreement for the Series B Preferred Stock), or 30,607 votes. The Series B Preferred Stock had no dividend, liquidation or other preferential rights (but had the redemption rights described below) to our common stock and could have been converted into shares of our common stock at a price equal to $53.55 per share upon the earlier of the date of closing to the extent that the holder thereof reallocated shares of our common stock reserved for issuance under its Notes to conversion of the Series B Preferred Shares and otherwise upon receipt of shareholder approval of the Reverse Stock Split. The Series B Preferred Stock allowed for optional redemption by the Company at any time after issuance or the holders at any time after the tenth business day prior to the maturity date. In the instance of a Financing, the Company was required to redeem the Series B Preferred Stock. The $360,000 difference between the redemption amount and the cash purchase price of the Series B Preferred Stock, as well as all issuance costs related to the Series B Preferred Stock, have been recorded as a deemed dividend. The Series B Preferred Stock was redeemed for $2,360,000 pursuant to the Restructuring Agreement signed on August 28, 2017 with one investor and upon a redemption notice from the second investor as discussed in further detail in Note 7. Series C Preferred Stock On September 12, 2017, our Board authorized the establishment of a new series of preferred stock designated as Series C Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock which was filed with the State of Delaware on September 20, 2017. On September 21, 2017, we entered into a securities purchase agreement with two of our investors which had purchased Notes, convertible into shares of our common stock pursuant to a certain June 6, 2016 securities purchase agreement, of $0.5 million aggregate purchase price for 590 shares of Series C Preferred Stock. The purchase of the Series C Preferred Stock is being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended. The Series C Preferred Stock shall be entitled to 1,484,061 votes and may only vote on approval of a reverse split of our outstanding common stock. The Series C Preferred Stock has no dividend, liquidation or other preferential rights to our common stock, and each share of Series C Preferred Stock shall be redeemable for the amount of $1,000.00, payable in cash per share at our written election, and must be redeemed by us no later than December 21, 2017. Because the Series C Preferred Stock is mandatorily redeemable, it has been recorded as a liability with the difference between the purchases price and the fair value being recognized over the term of the instrument. Additionally, all expenses related to the issuance of the Series C Preferred Stock are recognized as a debt discount and have been amortized over the term of the instrument. Per the terms of the October 22, 2017 Amendment to the Restructuring Agreement, the Series C Preferred Stock was redeemed for $590,000 on November 6, 2017. Warrants In October 2013, the Company completed the sale of 234 shares of its common stock and the issuance of warrants to purchase approximately 106 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At September 30, 2017, the 2013 Warrants were exercisable at $39,424.00 per share with approximately 100 warrants outstanding. The 2013 Warrants have a five-year term. In February 2015, the Company completed the sale of approximately 440 shares of its common stock and the issuance of warrants to purchase 197 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2017, the February 2015 Warrants were exercisable at $49.00 per share with approximately 100 warrants outstanding. The February 2015 Warrants have a five-year term. In July 2015, the Company completed the sale of approximately 1,715 Units consisting of approximately 1,715 shares of its common stock, Series A Warrants to purchase up to approximately 1,140 common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 1,715 common shares (“Series B Warrants”) and 1,140 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the three months ended March 31, 2016, approximately 285 Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 1,140 Series B Warrants expired on January 29, 2016 and the remaining liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 285 Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At September 30, 2017, the Series A Warrants were exercisable at $49.00 with approximately 500 warrants outstanding. The Series A Warrants have a five-year term. There were approximately 285 July 2015 Series A Warrants exercised during the nine months ended September 30, 2017 for proceeds of approximately $15,000. In October 2016, the Company completed the sale of approximately 1,215 shares of its common stock and the issuance of warrants to purchase 425 common shares (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At September 30, 2017, the October 2016 Warrants were exercisable at $49.00 per share with 200 warrants outstanding. The October 2016 Warrants have a five-year term. Stock Incentive Plans The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 34 and 573 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 304 shares, from 269 to 573 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of September 30, 2017 there were 55 A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant. For the three and nine months ended September 30, 2017, the Company recognized compensation expense of approximately $3,000 and $48,000, respectively, relating to stock options granted to employees. For the same periods in 2016, the Company recognized compensation expense of approximately $24,000 and $0.1 million, respectively. There were 43 stock options awards granted during the nine months ended September 30, 2017. There were no stock option awards granted during the same period in 2016. For the three and nine months ended September 30, 2017, the Company recognized compensation expense of approximately $20,000 and $0.1 million, respectively, relating to restricted stock granted to employees. For the same periods in 2016, the Company recognized compensation expense of approximately $38,000 and $0.2 million, respectively. There were 264 shares of restricted stock granted during the nine months ended September 30, 2017. There were approximately no shares of restricted stock awards granted for the same period in 2016.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(9) Fair Value Measurements Derivative Warrant Liability As disclosed in Note 8 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes discussed in further detail in Note 7 of the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. The valuation of the October 2013, February 2015, July 2015 Series A, June 2016 Series C and October 2016 warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy. For the three and nine months ended September 30, 2017, the Company recorded pre-tax derivative warrant income of approximately $27,000 and $1.2 million, respectively. The resulting derivative warrant liabilities totaled approximately $16,000 at September 30, 2017. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions: October 2016 Warrants July 2015 Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 142.46% 165.32% 181.24% 227.68% Risk-free interest rates 1.77% 1.59% 1.53% 1.33% Expected life (in years) 4.02 2.81 2.38 1.08 The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820. Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Level 1 Level 2 Level 3 Balance at September 30, 2017 Liabilities Derivative instrument liabilities $ — $ — $ 16 $ 16 For the periods ended September 30, 2017 and 2016, there were no transfers in or out of Level 1, 2 or 3 inputs. The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at December 31, 2016 $ 18,751 Total change in the liability included in earnings (1,227 ) Extinguishment of convertible note warrant (17,489 ) Fair value of warrants issued — Fair value of warrants exercised (19 ) Balance at September 30, 2017 $ 16

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss per Common Share	(10) Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. Additionally, for the periods ended September 30, 2017, the deemed dividend related to the Series B Preferred Stock (as discussed further in Note 8) is included with net loss to determine both the basic and diluted loss per share. The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive: September 30, 2017 2016 Stock options 155 118 Unvested restricted shares 289 54 Warrants 953 21,221 Total 1,397 21,394

Taxes

Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Taxes	(11) Taxes As discussed in Note 13 Income Taxes The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. During the third quarter of 2015, the Internal Revenue Service commenced an examination of the Company’s federal income tax return for the year ended December 31, 2013. The examination was completed in the third quarter of 2017 and no changes were made to the reported amounts. Accordingly, there was no effect on the financial statements as a result of the examination. The Company has not been audited by the international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	(12) Subsequent Events As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,550 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75 th The exercise price for the warrants issued in conjunction with the amended restructuring agreement is $122.50. The warrants contain a cashless exercise provision pursuant to which the warrants may be exercised for 382,650 shares of the Company’s common stock on or after the 75 th th st th On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s interim condensed consolidated financial statements contained in the Quarterly Report on Form 10-Q and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

General (Policies)

General (Policies)	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Liquidity and Operating Matters	Liquidity and Operating Matters The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $305.6 $12.6 $11.7 The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. As a result of issuing $35.0 million in senior secured convertible notes in June 2016 and effecting a reverse stock split on November 6, 2017 management believes that in its current reduced operating mode its capital resources will be adequate to fund operations through at least January 2018. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to clinical research, product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.
Basis of Presentation	Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2017 and 2016; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018. Due to the nature of the Company’s revenue generating activites and the small number of customer contracts, the Company does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of the following: (in thousands) September 30, 2017 December 31, 2016 Raw materials $ 328 $ 346 Work-in-process 660 214 Finished goods 176 100 Total inventories $ 1,164 $ 660

Prepaid Expenses and Other Cu23

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: (in thousands) September 30, 2017 December 31, 2016 Insurance premiums $ 61 $ 501 Taxes 53 — Security Deposit 50 50 Other 1 221 147 Total prepaid expenses and other current assets $ 385 $ 698 1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at September 30, 2017 and December 31, 2016.

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Components of property, plant and equipment	Property, plant, and equipment consist of the following: (in thousands) September 30, 2017 December 31, 2016 Buildings and land $ 574 $ 556 Enterprise hardware and software 1,648 1,532 Leaseholds 1,659 1,504 Equipment 960 940 Furniture 182 354 Property, plant and equipment, gross 5,023 4,886 Accumulated depreciation (3,770 ) (3,803 ) Property, plant and equipment, net $ 1,253 $ 1,083

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2017
Payables And Accruals [Abstract]
Schedule of accrued expenses	Accrued expenses consist of the following: (in thousands) September 30, 2017 December 31, 2016 Clinical trial expenses 1,410 1,365 Compensation, excluding taxes $ 1,132 $ 933 Professional fees 448 286 Short-term portion of lease restructuring 221 216 Other 1 544 607 Total accrued expenses $ 3,755 $ 3,407 1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at September 30, 2017 and December 31, 2016.

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	9 Months Ended
	Sep. 30, 2017
Restructuring And Related Activities [Abstract]
Schedule of restructuring and related costs	The following table provides the year-to-date activity of the Company’s restructuring reserves as of September 30, 2017: (in thousands) Lease Liability Reserve balance at December 31, 2016 $ 820 Charges — Payments/Utilizations (155 ) Reserve balance at September 30, 2017 $ 665

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Summary of Common Stock Shares Issued under Notes	The Company has issued shares of Common Stock as payments of principal (including certain early repayments at the option of the holders) under the Notes as follows: Number of Shares of Common Stock Number of Shares of Preferred Stock Applicable Conversion Price Reduction in Principal January 12, 2017 11,753 — $ 126.00 $ 1,478,318 January 26 - February 1, 2017 1 4,857 — $ 112.00 544,000 February 10, 2017 43,882 — $ 70.00 3,045,817 February 23 - March 2, 2017 1 2,571 — $ 49.00 126,000 March 13, 2017 117,297 — $ 38.50 4,417,830 April 10, 2017 169,061 — $ 21.00 3,621,286 May 9, 2017 109,367 — $ 17.50 1,913,915 June 7 / July 2, 2017 Exchange Agreement 2 689,796 4,200 $ 6.09 4,200,000 July 7, 2017 114,286 — $ 17.50 2,000,000 August 4, 2017 38,906 — $ 24.50 1,015,848 August 28, 2017 Restructuring Agreement 3 117,171 — $ 10.50 1,200,000 Total 1,418,948 $ 23,563,014 1 2 3
Summary of Convertible Notes Outstanding	The following table summarizes the convertible notes outstanding at September 30, 2017: (in thousands) Convertible notes payable, principal $ 11,437 Debt discounts (1,701 ) Net convertible note payable $ 9,736

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of fair value of the warrants	The fair value of the Warrants at September 30, 2017 was determined by using option pricing models with the following assumptions: October 2016 Warrants July 2015 Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 142.46% 165.32% 181.24% 227.68% Risk-free interest rates 1.77% 1.59% 1.53% 1.33% Expected life (in years) 4.02 2.81 2.38 1.08
Assets and liabilities measured at fair value on a recurring basis	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820. Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Level 1 Level 2 Level 3 Balance at September 30, 2017 Liabilities Derivative instrument liabilities $ — $ — $ 16 $ 16
Fair value measurements using significant unobservable inputs	The table below presents the activity within Level 3 of the fair value hierarchy for the nine months ended September 30, 2017: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at December 31, 2016 $ 18,751 Total change in the liability included in earnings (1,227 ) Extinguishment of convertible note warrant (17,489 ) Fair value of warrants issued — Fair value of warrants exercised (19 ) Balance at September 30, 2017 $ 16

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Anti-dilutive securities excluded from the computation of earnings per share	The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2017 and 2016 because their effects would be anti-dilutive: September 30, 2017 2016 Stock options 155 118 Unvested restricted shares 289 54 Warrants 953 21,221 Total 1,397 21,394

General - Additional Informatio

General - Additional Information (Details)	Nov. 06, 2017$ / sharesshares	Jul. 21, 2016$ / sharesshares	Sep. 30, 2017USD ($)$ / shares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)$ / shares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)$ / shares	Jun. 30, 2016USD ($)
Class Of Stock [Line Items]
Reverse stock split ratio		0.0625
Number of fractional shares were issued in connection with the reverse stock split | shares		0
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01		$ 0.01		$ 0.01
Net loss			$ 12,596,000	$ 1,004,000	$ 25,873,000	$ 9,485,000
Net cash used in operating activities					11,659,000	$ 10,597,000
Accumulated deficit			305,587,000		305,587,000		$ 279,188,000
Senior Secured Convertible Notes [Member]
Class Of Stock [Line Items]
Debt instrument, principal face amount			$ 11,437,000		$ 11,437,000			$ 35,000,000
Subsequent Event [Member]
Class Of Stock [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] | OTCQB [Member]
Class Of Stock [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split | shares	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 328	$ 346
Work-in-process	660	214
Finished goods	176	100
Total inventories	$ 1,164	$ 660

Prepaid Expenses and Other Cu32

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 61	$ 501
Taxes	53
Security Deposit	50	50
Other	221	147
Total prepaid expenses and other current assets	$ 385	$ 698

Prepaid Expenses and Other Cu33

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipmen34

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,023	$ 4,886
Accumulated depreciation	(3,770)	(3,803)
Property, plant and equipment, net	1,253	1,083
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	574	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,648	1,532
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,659	1,504
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	960	940
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 182	$ 354

Property, Plant, and Equipmen35

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 100	$ 100	$ 198	$ 232

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Clinical trial expenses	$ 1,410	$ 1,365
Compensation, excluding taxes	1,132	933
Professional fees	448	286
Short-term portion of lease restructuring	221	216
Other	544	607
Total accrued expenses	$ 3,755	$ 3,407

Accrued Expenses - Schedule o37

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details)	Sep. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Restructuring Expenses - Additi

Restructuring Expenses - Additional Information (Details) $ in Thousands	Aug. 18, 2014USD ($)	May 22, 2014USD ($)	Sep. 30, 2017USD ($)Lease	Dec. 31, 2016USD ($)
Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases | Lease			2
Restructuring reserve balance			$ 665	$ 820
Sub-lease 1 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Other non-current liabilities [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			400
Accrued Expenses [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 300

Restructuring Expenses - Schedu

Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) - Lease Liability [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 820
Payments/Utilizations	(155)
Restructuring reserve balance	$ 665

Convertible Notes Payable - Add

Convertible Notes Payable - Additional Information (Details)

Nov. 06, 2017

Oct. 11, 2017USD ($)d$ / shares

Oct. 10, 2017USD ($)Investor$ / sharesshares

Sep. 21, 2017USD ($)$ / shares

Sep. 15, 2017USD ($)$ / sharesshares

Aug. 28, 2017USD ($)$ / sharesshares

Aug. 04, 2017USD ($)$ / shares

Jul. 07, 2017USD ($)$ / shares

Jul. 02, 2017USD ($)$ / shares

May 09, 2017USD ($)$ / shares

Apr. 10, 2017USD ($)$ / shares

Apr. 02, 2017USD ($)

Mar. 13, 2017USD ($)$ / shares

Mar. 02, 2017USD ($)$ / shares

Feb. 10, 2017USD ($)$ / shares

Feb. 01, 2017USD ($)$ / shares

Jan. 12, 2017USD ($)$ / shares

Jul. 21, 2016

Jun. 13, 2016

Jun. 06, 2016USD ($)Installment$ / sharesshares

Dec. 31, 2016USD ($)

Sep. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Sep. 30, 2016USD ($)

Aug. 28, 2017USD ($)$ / sharesshares

Sep. 30, 2017USD ($)

Sep. 30, 2016USD ($)

Jun. 30, 2016USD ($)

Debt Instrument [Line Items]

Gain on warrant extinguishment

$ 0

$ 0

$ 9,613,000

$ 0

Warrant liability fair value adjustment

(27,000)

$ (8,680,000)

(1,227,000)

(9,171,000)

Debt instrument, conversion price | $ / shares

$ 24.50

$ 17.50

$ 17.50

$ 21

$ 38.50

$ 49

$ 70

$ 112

$ 126

Reverse stock split ratio

0.0625

Conversion of convertible notes

$ 1,015,848

$ 2,000,000

$ 1,913,915

$ 3,621,286

$ 4,417,830

$ 126,000

$ 3,045,817

$ 544,000

$ 1,478,318

$ 23,563,014

26,199,000

0

Subsequent Event [Member]

Debt Instrument [Line Items]

Reverse stock split ratio

0.0029

Restructuring Agreement [Member]

Debt Instrument [Line Items]

Conversion of convertible notes

$ 1,200,000

Restructuring Agreement [Member] | Investor [Member]

Debt Instrument [Line Items]

Initial release of restricted cash

1,650,000

Restructuring Agreement [Member] | Investor [Member] | Notes [Member]

Debt Instrument [Line Items]

Aggregate principal amount of notes

$ 11,444,637

$ 11,444,637

Additional Restructuring [Member] | Investor [Member]

Debt Instrument [Line Items]

Reverse stock split ratio

20

Additional Restructuring [Member] | Investor [Member] | New Warrants [Member]

Debt Instrument [Line Items]

Shares issuable upon warrants exercised | shares

2.125

Warrants expiry period

42 months

Exercise price of warrants | $ / shares

$ 122.50

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Exercise price of warrants | $ / shares

$ 122.50

Warrants issued to purchase Common Stock | shares

127,551

Series A and Series B Preferred Shares [Member]

Debt Instrument [Line Items]

Payment for redemption of preferred stock

2,360,000

0

Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Preferred stock redemption price per share | $ / shares

$ 0.001

Series A Preferred Stock [Member] | Restructuring Agreement [Member] | Investor [Member]

Debt Instrument [Line Items]

Number of preferred stock | shares

4,200

4,200

Preferred stock redemption price per share | $ / shares

$ 4.20

$ 4.20

Series B Convertible Preferred Stock [Member] | Restructuring Agreement [Member] | Investor [Member]

Debt Instrument [Line Items]

Number of preferred stock | shares

2,006

2,006

Series B Preferred Stock [Member] | Restructuring Agreement [Member] | Investor [Member]

Debt Instrument [Line Items]

Payment for redemption of preferred stock

$ 2,006,000

Series C Preferred Shares [Member]

Debt Instrument [Line Items]

Preferred stock redemption price per share | $ / shares

$ 1,000

Conversion of convertible notes

$ 500,000

Series C Preferred Shares [Member] | Amendment to Restructuring Agreement [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Redemption of shares outstanding for cash payment

$ 590,000

Securities Purchase Agreement [Member] | Warrant Repurchase Agreements [Member]

Debt Instrument [Line Items]

Aggregate amount to be paid in exchange for cancellation of warrants

$ 7,900,000

Gain on warrant extinguishment

9,600,000

Warrant liability fair value adjustment

$ 17,500,000

Senior Secured Convertible Notes [Member]

Debt Instrument [Line Items]

Debt instrument, principal face amount

11,437,000

11,437,000

$ 35,000,000

Debt discount on senior notes

1,701,000

1,701,000

Senior Secured Convertible Notes [Member] | Amendment to Restructuring Agreement [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Debt instrument, conversion price | $ / shares

$ 0.05

Number of Notes investors entered into agreement | Investor

2

Conversion of convertible notes

$ 279,015

Conversion price of debt instrument to purchase price of common stock percentage.

200.00%

Debt instrument, maturity description

The maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018

Debt instrument maturity date

Dec. 30, 2018

Debt instrument, deferred description

Until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period

Debt instrument, conversion treshold days | d

75

Debt instrument, redemption description

The Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes

Redemption of outstanding debt instrument for cash

$ 7,300,000

Senior Secured Convertible Notes [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Conversion of convertible notes

$ 4,200,000

Senior Secured Convertible Notes [Member] | Series C Preferred Shares [Member] | Amendment to Restructuring Agreement [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Cash held in the restricted accounts

$ 600,000

Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Debt instrument, principal face amount

$ 35,000,000

Debt discount on senior notes

2,800,000

$ 35,000,000

$ 35,000,000

Interest rate upon default

0.00%

0.00%

Rate of interest in event of default

15.00%

Debt instrument interest rate computation terms

The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default, at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable

Proceeds from issuance of notes available for general corporate purposes

$ 3,000,000

$ 3,000,000

$ 2,100,000

$ 6,600,000

Amortization payments number of equal installments | Installment

14

Period after original date of issuance of notes for which amortization payment begins

7 months

Debt instrument, original issuance date

Jun. 13, 2016

Debt instrument, conversion price | $ / shares

$ 1,536.50

Debt discount amortization

$ 33,300,000

Beneficial conversion feature

4,400,000

Debt instrument, put options issued on default and change in control, value

0

0

Debt issuance costs

1,800,000

1,800,000

Amortization of debt issuance costs

1,200,000

Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Series A and Series B Preferred Shares [Member]

Debt Instrument [Line Items]

Payment for redemption of preferred stock

$ 2,400,000

Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Restricted Cash [Member]

Debt Instrument [Line Items]

Proceeds from issuance of notes and warrants

7,300,000

Restricted Notes [Member] | Restructuring Agreement [Member] | Investor [Member] | Notes [Member]

Debt Instrument [Line Items]

Aggregate principal amount of notes

10,092,857

$ 10,092,857

Unrestricted Notes [Member] | Restructuring Agreement [Member] | Investor [Member] | Notes [Member]

Debt Instrument [Line Items]

Aggregate principal amount of notes

1,351,780

$ 1,351,780

Cancellation Note [Member] | Restructuring Agreement [Member] | Investor [Member]

Debt Instrument [Line Items]

Aggregate principal of notes cancelled

$ 1,200,000

Redemption Notes [Member] | Additional Restructuring [Member] | Investor [Member]

Debt Instrument [Line Items]

Debt instrument, principal face amount

$ 4,000,000

Debt instrument, redemption price

6,436,852.80

Exchange Notes | Additional Restructuring [Member] | Investor [Member]

Debt Instrument [Line Items]

Debt instrument, principal face amount

$ 2,436,852.80

Exchange Notes | Additional Restructuring [Member] | Investor [Member] | New Warrants [Member]

Debt Instrument [Line Items]

Common stock shares purchased | shares

114,286

Series C Warrants [Member]

Debt Instrument [Line Items]

Aggregate amount to be paid in exchange for cancellation of warrants

$ 7,876,000

$ 0

Series C Warrants [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Additional issuance of common stock purchase price per share. | $ / shares

$ 0.01

Series C Warrants [Member] | Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Proceeds from issuance of notes and warrants

$ 32,200,000

Debt discount on senior notes

$ 27,800,000

Shares issuable upon warrants exercised | shares

20,000

Convertible Notes Payable - Sum

Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Details) - USD ($)	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Aug. 28, 2017	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Applicable Conversion Price		$ 24.50	$ 17.50		$ 17.50	$ 21	$ 38.50	$ 49	$ 70	$ 112	$ 126
Reduction in Principal		$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318	$ 23,563,014	$ 26,199,000	$ 0
Exchange Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price				$ 6.09
Reduction in Principal				$ 4,200,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price	$ 10.50											$ 10.50
Reduction in Principal	$ 1,200,000
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of Shares		38,906	114,286		109,367	169,061	117,297	2,571	43,882	4,857	11,753	1,418,948
Common Stock Issued [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				689,796
Common Stock Issued [Member] | Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	117,171
Preferred Stock Issued [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				4,200

Convertible Notes Payable - S42

Convertible Notes Payable - Summary of Common Stock Shares Issued under Notes (Parenthetical) (Details) - USD ($)	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Sep. 30, 2017	Aug. 28, 2017	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Reduction in Principal		$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,830	$ 126,000	$ 3,045,817	$ 544,000	$ 1,478,318		$ 23,563,014	$ 26,199,000	$ 0
Loss on debt settlement												$ 2,952,000		$ 2,952,000	$ 0
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 1,200,000
Loss on debt settlement	$ 2,000,000
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued		38,906	114,286		109,367	169,061	117,297	2,571	43,882	4,857	11,753		1,418,948
Common Stock Issued [Member] | Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued	117,171
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued				4,200
Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal				$ 4,200,000
Loss on debt settlement				$ 1,000,000
Exchange Agreement [Member] | Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued				689,796
Exchange Agreement [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued				4,200

Convertible Notes Payable - S43

Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) - Senior Secured Convertible Notes [Member] - USD ($)	Sep. 30, 2017	Jun. 30, 2016
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 11,437,000	$ 35,000,000
Debt discounts	(1,701,000)
Net convertible note payable	$ 9,736,000

Stockholders' Equity - Reverse

Stockholders' Equity - Reverse Stock Split - Additional Information (Details)	Nov. 06, 2017$ / sharesshares	Jul. 21, 2016$ / sharesshares	Jul. 19, 2016shares	Sep. 30, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares	Jul. 18, 2016shares
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.0625
Number of fractional shares were issued in connection with the reverse stock split		0
Common stock, par value (in dollars per share) | $ / shares		$ 0.01		$ 0.01	$ 0.01
Common stock, shares authorized (in shares)			500,000,000	500,000,000	500,000,000	170,000,000
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio			0.05
Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Subsequent Event [Member] | OTCQB [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0029
Number of fractional shares were issued in connection with the reverse stock split	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01

Stockholders' Equity - Recent P

Stockholders' Equity - Recent Preferred Stock Issuances - Additional Information (Details)

Sep. 21, 2017USD ($)InvestorVote$ / sharesshares

Aug. 28, 2017USD ($)shares

Aug. 04, 2017USD ($)

Jul. 11, 2017USD ($)Vote$ / shares

Jul. 07, 2017USD ($)

Jul. 02, 2017USD ($)Vote$ / sharesshares

May 09, 2017USD ($)

Apr. 10, 2017USD ($)

Mar. 13, 2017USD ($)

Mar. 02, 2017USD ($)

Feb. 10, 2017USD ($)

Feb. 01, 2017USD ($)

Jan. 12, 2017USD ($)

Oct. 31, 2016USD ($)

Feb. 28, 2015USD ($)

Oct. 31, 2013USD ($)

Sep. 30, 2017USD ($)$ / shares

Aug. 28, 2017USD ($)shares

Sep. 30, 2017USD ($)$ / shares

Sep. 30, 2016USD ($)

Nov. 06, 2017USD ($)

Sep. 12, 2017$ / shares

Jun. 29, 2017$ / shares

Dec. 31, 2016$ / shares

Stockholders Equity Note [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.01

$ 0.01

$ 0.01

Conversion of convertible notes

$ 1,015,848

$ 2,000,000

$ 1,913,915

$ 3,621,286

$ 4,417,830

$ 126,000

$ 3,045,817

$ 544,000

$ 1,478,318

$ 23,563,014

$ 26,199,000

$ 0

Gross proceeds from the sale of shares

$ 1,200,000

$ 2,600,000

$ 7,500,000

Restructuring Agreement [Member]

Stockholders Equity Note [Line Items]

Conversion of convertible notes

$ 1,200,000

Series A Preferred Stock [Member]

Stockholders Equity Note [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.01

Number of Shares | shares

4,200

Closing bid price | $ / shares

$ 1,288

Number of votes | Vote

3,261

Preferred stock redemption price per share | $ / shares

$ 0.001

Series B Preferred Stock [Member]

Stockholders Equity Note [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.01

Closing bid price | $ / shares

$ 65.35

Number of votes | Vote

30,607

Sale of stock in private placement

$ 2,360,000

Cash purchase price in private placement

2,000,000

Gross proceeds from the sale of shares

$ 2,000,000

Conversion price per share | $ / shares

$ 53.55

Deemed dividend amount

$ 360,000

Series B Preferred Stock [Member] | Restructuring Agreement [Member]

Stockholders Equity Note [Line Items]

Redeemed share | shares

2,360,000

2,360,000

Series C Preferred Shares [Member]

Stockholders Equity Note [Line Items]

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.01

Conversion of convertible notes

$ 500,000

Number of Shares | shares

590

Number of votes | Vote

1,484,061

Preferred stock redemption price per share | $ / shares

$ 1,000

Number of investors | Investor

2

Redemption of preferred stock

$ 590,000

Senior Secured Convertible Notes [Member] | Series A Preferred Stock [Member]

Stockholders Equity Note [Line Items]

Conversion of convertible notes

$ 4,200,000

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants - Additional Information (Details) - USD ($)	1 Months Ended				9 Months Ended
	Oct. 31, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Sep. 30, 2017
Class Of Warrant Or Right [Line Items]
Sale of common stock, net of expenses (in shares)	1,215	1,715	440	234
Proceeds from issuance of private placement	$ 1,200,000		$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement	$ 1,100,000		$ 2,500,000	$ 6,900,000
Sale of units to underwriter		1,715
Proceeds of common stock issued, net of related expenses		$ 6,000,000
Series A Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercisable per share price (in dollars per share)					$ 49
Number of warrants outstanding (in shares)					500
Number of warrants converted		1,140			285
Gross proceeds from underwriting offering		$ 7,000,000
Warrants expiry period					5 years
Warrants exercised (in shares)					285
Net proceeds from exercise of warrants					$ 15,000
Series B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants converted		1,715
Warrants exercised (in shares)					285
Net proceeds from exercise of warrants					$ 800,000
Remaining outstanding warrants expired					1,140
Warrants expiration date					Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Value of warrants issued		$ 3,400,000
2013 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)				106
Value of warrants issued				$ 1,900,000
Warrants exercisable per share price (in dollars per share)					$ 39,424
Number of warrants outstanding (in shares)					100
Term period for warrants					5 years
February 2015 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)			197
Value of warrants issued			$ 800,000
Warrants exercisable per share price (in dollars per share)					$ 49
Number of warrants outstanding (in shares)					100
Term period for warrants					5 years
October 2016 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued (in shares)	425
Value of warrants issued	$ 300,000
Warrants exercisable per share price (in dollars per share)					$ 49
Number of warrants outstanding (in shares)					200
Term period for warrants					5 years

Stockholders' Equity - Stock In

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense				$ 48,000	$ 138,000
Restricted stock compensation expense				84,000	228,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 3,000	$ 24,000	$ 48,000	$ 100,000
Stock options granted				43	0
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, term				10 years
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				264	0
Restricted stock compensation expense		$ 20,000	$ 38,000	$ 100,000	$ 200,000
2004 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		34		34
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	269	573		573
Increased number of shares (in shares)	304
Shares available for grant		55		55

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)Input	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Fair Value Disclosures [Abstract]
Number of inputs used for valuation of warrants | Input			6
Derivative warrant liability [Abstract]
Change in fair value of the warrant liability, net	$ (27,000)	$ (8,680,000)	$ (1,227,000)	$ (9,171,000)
Derivative warrant liabilities	$ 16,000		$ 16,000		$ 18,751,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Warrants (Details)	9 Months Ended
	Sep. 30, 2017
October 2016 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	142.46%
Risk-free interest rates (in hundredths)	1.77%
Expected life (in years)	4 years 7 days
July 2015 Series A Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	165.32%
Risk-free interest rates (in hundredths)	1.59%
Expected life (in years)	2 years 9 months 22 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	181.24%
Risk-free interest rates (in hundredths)	1.53%
Expected life (in years)	2 years 4 months 17 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	227.68%
Risk-free interest rates (in hundredths)	1.33%
Expected life (in years)	1 year 29 days

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Derivative Instruments Liabilities [Member] - Recurring [Member] $ in Thousands	Sep. 30, 2017USD ($)
Liabilities [Abstract]
Total Liabilities	$ 16
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 16

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 18,751
Total change in the liability included in earnings	(1,227)
Extinguishment of convertible note warrant	(17,489)
Fair value of warrants issued	0	$ 28,133
Fair value of warrants exercised	(19)	$ (245)
Ending balance	$ 16

Net Loss per Common Share - Ant

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,397	21,394
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	155	118
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	289	54
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	953	21,221

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)

Nov. 06, 2017USD ($)$ / sharesshares

Oct. 11, 2017USD ($)Conversion$ / shares

Oct. 10, 2017USD ($)Investord$ / sharesshares

Sep. 21, 2017USD ($)

Aug. 04, 2017USD ($)$ / shares

Jul. 07, 2017USD ($)$ / shares

May 09, 2017USD ($)$ / shares

Apr. 10, 2017USD ($)$ / shares

Mar. 13, 2017USD ($)$ / shares

Mar. 02, 2017USD ($)$ / shares

Feb. 10, 2017USD ($)$ / shares

Feb. 01, 2017USD ($)$ / shares

Jan. 12, 2017USD ($)$ / shares

Jul. 21, 2016$ / sharesshares

Aug. 28, 2017USD ($)

Sep. 30, 2017USD ($)$ / shares

Sep. 30, 2016USD ($)

Dec. 31, 2016$ / shares

Subsequent Event [Line Items]

Conversion of convertible notes

$ 1,015,848

$ 2,000,000

$ 1,913,915

$ 3,621,286

$ 4,417,830

$ 126,000

$ 3,045,817

$ 544,000

$ 1,478,318

$ 23,563,014

$ 26,199,000

$ 0

Debt instrument, conversion price | $ / shares

$ 24.50

$ 17.50

$ 17.50

$ 21

$ 38.50

$ 49

$ 70

$ 112

$ 126

Reverse stock split ratio

0.0625

Number of fractional shares were issued in connection with the reverse stock split | shares

0

Common stock, par value (in dollars per share) | $ / shares

$ 0.01

$ 0.01

$ 0.01

Series C Preferred Shares [Member]

Subsequent Event [Line Items]

Conversion of convertible notes

$ 500,000

Preferred shares outstanding for a cash payment

$ 590,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Reverse stock split ratio

0.0029

Subsequent Event [Member] | OTCQB [Member]

Subsequent Event [Line Items]

Reverse stock split ratio

0.0029

Number of fractional shares were issued in connection with the reverse stock split | shares

0

Common stock, par value (in dollars per share) | $ / shares

$ 0.01

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Exercise price of warrants | $ / shares

$ 122.50

Warrants exercise price description

On the 136th day subsequent to the date of consummation of the offering hereunder, there shall be a “true up” with regard to the issuance of shares upon exercise such that the difference between 382,650 shares and the number of shares that would be issuable if the exercise price were lowered to the average price per share of the variable weighted average price of our common stock for the five trading days commencing on the date which is 76 days after the date of consummation of the offering hereunder, but not lower than 33% of the variable weighted average price of a share of our common stock on the 81st date following the date of consummation of the offering hereunder.

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | On Or After 75th Day Subsequent To Date of Consummation of Offering [Member]

Subsequent Event [Line Items]

Shares issuable upon warrants exercised | shares

382,650

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | After 76 Days from Date of Consummation of Offering [Member]

Subsequent Event [Line Items]

Number of trading days required to measure weighted average price of common stock | d

5

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | On 81st Date Following from Date of Consummation of Offering [Member]

Subsequent Event [Line Items]

Minimum percentage of variable weighted average price of share of common stock

33.00%

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | On Or Before 135th Date Following From Date of Consummation of Offering [Member]

Subsequent Event [Line Items]

Warrants provision may buy out

$ 6,138,349.80

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | Senior Secured Convertible Notes [Member]

Subsequent Event [Line Items]

Number of Notes investors entered into agreement | Investor

2

Conversion of convertible notes

$ 279,015

Registration statement on Form S-1 filed date

Oct. 11, 2017

Conversion price of debt instrument to purchase price of common stock percentage.

200.00%

Debt instrument maturity date

Dec. 30, 2018

Conversions during 75 day period from date of consummation | Conversion

0

Redemption of outstanding debt instrument for cash

$ 7,300,000

Debt instrument, conversion price | $ / shares

$ 0.05

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | Common Stock Issued [Member]

Subsequent Event [Line Items]

Shares issuable upon warrants exercised | shares

127,550

Amendment to Restructuring Agreement [Member] | Subsequent Event [Member] | Series C Preferred Shares [Member]

Subsequent Event [Line Items]

Preferred shares outstanding for a cash payment

$ 590,000